Abstract:Purpose: The primary aim of this study was to investigate, using an experimental rat model of osteoarthritis(OA), the effect of a selective p38 mitogen activated protein kinase inhibitor,SB203580, on the development of structural changes.Additional aims were to assess the effects of the inhibitor on levels of matrixmetalloproteinase 3 (MMP-3) and MMP-13(collagenase 3) in OA cartilage and to explore the relation between the MMP-3,13 expression and the severity of OA. Methods: OA was induced in 40 SD rats by anterior cruciate ligament transection (ACLT).After surgical, rats with OA were randomly divided into A_D groups: Rats of group A received 0.1 ml intra-articular injection of SB203580 at high concentration of 100um/L. Each treatment started immediately after surgery, once a week;those in group B were treated under the same condition using SB203580 with low concentration of 10um/L and those in group C received 0.1ml of intra-articular 0.9% Sodium Chloride injection,animals of group D were not injected as controls after ACLT. The animals were killed 8 weeks after surgery. Macroscopicand histologic studies were performed on the cartilage. The levels of MMP-3,13 in OA cartilage chondrocytes were evaluated by immunohistochemistry and western-blotting. Results: All ACLT knees demonstrated osteoarthritic changes. Cartilage degradation in the control group was significantly more severe than that in the experimental group both on the macroscopic grading scale and on Mankin’s grading scale(P <0.05). Immunohistochemical study showed that in the experimental group MMP-3,13 was predominantly expressed in the superficial and upper intermediate layers of cartilage, and the amount of MMP-3,13 in the experimental group was also lower than that in control group(P <0.05). In western-blotting the amount of MMP3,13 was reduced by the treatment of the inhibitor. The protein levels of MMP-3 and MMP-13 in cartilage of inhibitor injection groups were significantly lower than those of Sodium Chloride group and untreated group. There was no significant difference in MMP-3 and MMP-13 expression between the different concentration inhibitor injection groups. No significant difference in MMP-3 and MMP-13 expression in cartilage was found between Sodium Chloride group and control group. Conclusions: This study demonstrates that, in vivo,SB203580, a selective inhibitor of p38MAPK, can partially decrease the development of some of the structural changes in the early phases of experimental OA and significantly reduces the severity of cartilage degradation. This effect was associated with a reduction in the level of MMP-3,13 in OA cartilage, which probably explains the action of the drug and thus may be a potential drug for the treatment of OA.

Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis

Polygalacic Acid Inhibits MMPs Expression and Osteoarthritis Via Wnt/β-catenin and MAPK Signal Pathways Suppression

Screening of MMP-13 Inhibitors Using a GelMA-Alginate Interpenetrating Network Hydrogel-Based Model Mimicking Cytokine-Induced Key Features of Osteoarthritis In Vitro

Morin exerts antiosteoarthritic properties: an in vitro and in vivo study.

P173 THE EFFECTS OF INTRA-ARTICULAR INJECTION OF P38 MAPK INHIBITOR ON MATRIX METALLOPROTEINASE IN CARTILAGE OF EXPERIMENTAL OSTEOARTHRITIS MODEL

The Pharmacology of Pain Associated With the Monoiodoacetate Model of Osteoarthritis

Baicalein Inhibits MMPs Expression via a MAPK-Dependent Mechanism in Chondrocytes.

On-demand Release of a Selective MMP-13 Blocker from an Enzyme-Responsive Injectable Hydrogel Protects Cartilage from Degenerative Progression in Osteoarthritis

Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis

Pharmacological characterization of the chronic phase of the monoiodoacetate-induced rat model of osteoarthritis pain in the knee joint

AMD3100 attenuates MMP-3 and MMP-9 expressions and prevents cartilage degradation in a monosodium iodoacetate-induced rat model of temporomandibular osteoarthritis

A systematic computational analysis of human matrix metalloproteinase 13 (MMP-13) crystal structures and structure-based identification of prospective drug candidates as MMP-13 inhibitors repurposable for osteoarthritis

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis

[Effects of Intra-Articular Injection of P38 Mitogen-Activated Protein Kinase Inhibitor on Matrix Metalloproteinase in Articular Cartilage of a Rat Model of Osteoarthritis].

Comparison of chemical-induced temporomandibular osteoarthritis rat models (monosodium iodoacetate versus collagenase type II) for the study of prolonged drug delivery systems

Biocompatible Solutions: Evaluating the Safety of Repeated Intra-Articular Injections of pMPCylated Liposomes for Knee Osteoarthritis Therapy in Rat Models

In Vitro Evaluation of the Anti-Inflammatory Effect of KMUP-1 and In Vivo Analysis of Its Therapeutic Potential in Osteoarthritis

Proteolysis of the Pericellular Matrix: Pinpointing the Role and Involvement of Matrix Metalloproteinases in Early Osteoarthritic Remodeling

Clinical efficacy of mesenchymal stem cells and platelet-rich plasma in the therapy of osteoarthritis: a meta-analysis

Oxaprozin: A new hope in the modulation of matrix metalloproteinase 9 activity

Ε-Poly-l-lysine As an Efficient Cartilage Penetrating and Residing Drug Carrier with High Intraarticular Injection Safety for Treating Osteoarthritis